1. �Ϻ��и�����ѧ������ɽҽԺƤ����
2. ������ѧ������ɽҽԺƤ����

��ͻϸ����һ��רְ�Ŀ�ԭ���ϸ���������в�ͬ����Ⱥ�������߷�Ӧ�У���ͻϸ���ܴ�΢���Ｐϸ���ܱ߻����н����źŴӶ������͵������߷�Ӧ����ͻϸ�������ﲻͬ��΢�������壬ϸ����������ͱ�����ӡ��书��״̬�������Ǽ������߷�Ӧ�����յ��������ܡ���ˣ��쳣����״̬����ͻϸ����������ͬ��Ƥ�������������������Լ����Ͱ�֢����֮����ͻϸ��Ҳ�ɱ��������Ƴ���������������Щ������

Dendritic cells ��DCs��, a subset of professional antigen-presenting cells, are classified into different subtypes. DCs can initiate and regulate immune responses after receiving signals from microbes and extracellular environment. They express different microbial receptors, cytokine receptors and surface molecules. The functional status of DCs determines whether they trigger immune response or induce immunotolerance. Hence, DCs with abnormal function can result in different skin diseases, including autoimmune diseases and cancers. Conversely, DCs can also be exploited for the development of vaccines to treat these diseases.

�ο����� [1] Briere F, Bendriss-Vermare N, DelaleT, et al. Origin and filiation of human plasmacytoid dendritic cells. Hum Immunol, 2002,63(12): 1081–1093. [2] Rutella S, Danese S, Leone G, et al. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood, 2006, 108(5): 1435–1440. [3] Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med, 2006, 203(4): 871–881. [4] Mahnke K, Ring S, Johnson TS, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4(+)CD25(+) regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol, 2007, 37(8): 2117–2126. [5] Buisson S, Triebel F. LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology, 2005, 114(3): 369–374. [6] Forster R, Davalos-Misslitz AC, Rot A, et al. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol, 2008, 8(5): 362–371. [7] Min SY, Park KS, Cho ML, et al. Antigen-induced, tolerogenic CD11c+,CD11b+ dendritic cells are abundant in Peyer’s patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum, 2006, 54(3): 887–898. [8] Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cel differentiation by IFN-alpha in systemiclupus erythematosus. Science, 2001, 294(5546): 1540–1543. [9] Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA , 2005, 102: (52): 19057–19062. [10] Dunn GP, old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol, 2004, 22: 329-360. [11] Luftl M, Feng A, Licha E, et al. Dendritic cells and apoptosis in mycosis fungoides. British Journal of Dermatology, 2002, 147(6): 1171–1179. [12] Schlapbach C, Ochsenbein A , Kaelin U, et al. High numbers of DC-SIGN plus dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol, 2010, 62(6): 995-1004. [13] Steinbrink K, Jonuleit H, Muller G, et al. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood, 1999, 93(5): 1634–1642. [14] Wang TH, Niu GL, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med, 2004, 10(1): 48–54. [15] Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res , 2001, 23(2-3): 263–272.